Literature DB >> 11150107

Deaths attributable to methadone vs buprenorphine in France.

M Auriacombe, P Franques, J Tignol.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11150107     DOI： 10.1001/jama.285.1.45

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  36 in total

1.  Policy progress for physician treatment of opiate addiction.

Authors:  Joseph O Merrill
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

2.  Nonmedical use and abuse of scheduled medications prescribed for pain, pain-related symptoms, and psychiatric disorders: patterns, user characteristics, and management options.

Authors:  Meredith Y Smith; George Woody
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

Review 3.  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Authors:  Alexander Elkader; Beth Sproule
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder.

Authors:  Ryan Marino; Jeanmarie Perrone; Lewis S Nelson; Timothy J Wiegand; Evan S Schwarz; Paul M Wax; Andrew I Stolbach
Journal:  J Med Toxicol       Date:  2019-08-14

5.  Management of opioid use disorders: a national clinical practice guideline.

Authors:  Julie Bruneau; Keith Ahamad; Marie-Ève Goyer; Ginette Poulin; Peter Selby; Benedikt Fischer; T Cameron Wild; Evan Wood
Journal:  CMAJ       Date:  2018-03-05       Impact factor: 8.262

6.  Increasing diversion of methadone in Vancouver, Canada, 2005-2015.

Authors:  Hudson Reddon; Joel Ho; Kora DeBeck; M-J Milloy; Yang Liu; Huiru Dong; Keith Ahamad; Evan Wood; Thomas Kerr; Kanna Hayashi
Journal:  J Subst Abuse Treat       Date:  2017-11-28

7.  Buprenorphine: a (relatively) new treatment for opioid dependence.

Authors:  Christopher Welsh; Adela Valadez-Meltzer
Journal:  Psychiatry (Edgmont)       Date:  2005-12

8.  Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.

Authors:  George E Woody; Sabrina A Poole; Geetha Subramaniam; Karen Dugosh; Michael Bogenschutz; Patrick Abbott; Ashwin Patkar; Mark Publicker; Karen McCain; Jennifer Sharpe Potter; Robert Forman; Victoria Vetter; Laura McNicholas; Jack Blaine; Kevin G Lynch; Paul Fudala
Journal:  JAMA       Date:  2008-11-05       Impact factor: 56.272

9.  Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system.

Authors:  Roberto Ciccocioppo; Daina Economidou; Roberto Rimondini; Wolfgang Sommer; Maurizio Massi; Markus Heilig
Journal:  Biol Psychiatry       Date:  2006-03-14       Impact factor: 13.382

10.  Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey.

Authors:  Amy Nunn; Nickolas Zaller; Samuel Dickman; Catherine Trimbur; Ank Nijhawan; Josiah D Rich
Journal:  Drug Alcohol Depend       Date:  2009-07-21       Impact factor: 4.492
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.